We isolated IFN-ζ/Limitin, which was characterized by weak myelosuppressive properties. We have clarified signals for IFN-induced myelosuppression; the central signals from Tyk2 to Daxx and the sumoylation signals of Daxx. With a screening based on the cancellation of the IFN-signals, we are now trying to identify low molecular weight compounds.
IFNs are clinically used for the treatment of patients with virus-induced hepatitis as well as a variety of malignancies. However, we sometimes experience dose-reduction or interruption of the treatment because of major adverse effects such as myelosuppression. Our possible compounds will help us to treat patients with IFNs safely through controlling IFN-adverse effects.
